


Hippocampal Sparing Whole Brain: Rapid Plan Model Following the NRG-CC001 Protocol¹

Vanessa Magliari, CMD; Anthony Magliari, MS CMD; Robert Foster, MS DABR CMD

Introduction

Problem: Treatment plans often have high inter-planner variability and are time consuming to create.




There is a large inter-planner variation in plan quality as defined by a quantitative PGM score that measures the ability of the planner to meet very specific plan objectives. Plan quality was not statistically different between different TPS or delivery techniques and was not correlated to metrics of plan complexity. Certification and education demographics, experience, and confidence level of the planner were not good predictors of plan quality².

Solution: Use knowledge based planning, which has an origin in artificial intelligence and computer science, it involves training a learning system with a plurality of observed facts³.

Methods

Model Training:

The Hippocampal Sparing Whole Brain (HCSWB) model was trained with 20 cases. All cases were planned to 30Gy in 3Gy fractions with 6X energy on a Varian Linac with Millennium120 MLC, and utilized VMAT technique. The training cases were extracted from clinical cases that satisfied the contouring criteria. A recursive method of model creation was utilized to generate a RapidPlan model with very consistent, high quality plans developed with tight DVH prediction bands allowing for aggressive hippocampal sparing optimization objectives to be used.



An initial RapidPlan model is created from 20 manually planned cases. Then, that model is used to re-plan all the cases in that training set and/or others. Different arc geometries and differing combinations of auto-created optimization objectives are systematically used. The best scoring plan from each method is selected for each patient and those plans become the training set for the final model, and a final set of automatic objectives are then established for this final model. One RapidPlan model created from another initial/parent model – the recursive model creation process.

Model Validation:


The HCSWB model was validated using 21 cases which included the 20 final model training cases as well as an independent control case. Additional validation was done using 7 cases obtained from a separate outside institution. Since finalizing this model it has been tested on a number of cases from multiple institutions and the resulting plans were judged to have clinically satisfactory results, with Plan Quality Metric scores all within the expected range.

Methods


Plan Quality Metric (PQM) used to assess quality of plans
Scorecards were created for each plan using a Plan Quality Metric (PQM). The metrics were created from the criteria of the NRG-CC001 Protocol, with direct guidance added from a physician with experience treating hippocampal sparing whole brain patients under protocol. This guidance resulted in a more extreme hippocampal sparing than is requested by the protocol. The PQM scorecards were created using the Plan IQ software from Sun Nuclear Corporation. Building scorecards to guide plan quality throughout the model creation process proved to be critical. PQM scorecards enabled a very minute degree of plan quality control and measure throughout the model creation process and removed subjectivity in judging which plan was superior when assessing multiple plans for the same patient.

Plan Quality Scorecard:	Plan IQ				
This is the Plan Quality results generated for Plan Quality Algorithm					
Raw PGM / Max PGM	91.55 / 100.00 PGM %: 91.55				
Plan Quality Component	Requirement	Result	Raw Score	Max Score	Performance Comment
PTV_WB V10(Dx) (Gy)	> 90 (1: 25)	95.2056	10.00	10.00	100% (PDR Synchrony)
PTV_WB D10(Dx) (Gy)	> 22.5 (1: 25)	27.3563	13.00	13.00	100% (PDR Synchrony)
PTV_WB D12(Dx) (Gy)	> 40 (1: 37.5)	34.5462	13.00	13.00	100% (PDR Synchrony)
PTV_WB Homogeneity Index (D10)	< 0.9 (1: 0.8)	0.9416	1.25	2.00	62.5% (PDR Synchrony)
PTV_WB Conformity Number (D10.5Gy)	< 0.3 (1: 3)	0.7471	0.64	1.00	63.9% (PDR Synchrony)
HIPPOCAMPUS_TOTL D10(Dx) (Gy)	> 17 (1: 18)	34.1865	4.22	20.00	21.1%
HIPPOCAMPUS_TOTL Mean dose (Gy)	< 12 (1: 8)	8.8854	7.75	10.00	77.5%
HIPPOCAMPUS_TOTL D10(Dx) (Gy)	> 10 (1: 7)	7.1818	13.15	14.00	94.6%
CHIASM D10(Dx) (Gy)	> 37.5 (1: 30)	30.0411	2.90	3.00	96.7%
BRAINSTEM D10(Dx) (Gy)	> 37.5 (1: 33)	32.6464	3.00	3.00	100%
ICOM D10(Dx) (Gy)	> 37.5 (1: 25)	24.4075	3.00	3.00	100%
LOOPTIC D10(Dx) (Gy)	> 37.5 (1: 30)	30.0012	3.00	3.00	100%
PROPTIC D10(Dx) (Gy)	> 37.5 (1: 30)	29.9942	3.00	3.00	100%
LENT Mean dose (Gy)	> 15 (1: 4)	7.8079	2.40	3.00	79.6%
RETL Mean dose (Gy)	> 15 (1: 4)	7.7985	2.40	3.00	79.6%
BLACRIMALL Mean dose (Gy)	> 20 (1: 10)	8.6252	3.00	3.00	100%
BLACRIMALL Mean dose (Gy)	> 20 (1: 10)	8.2258	3.00	3.00	100%
LENT D10(Dx) (Gy)	> 10 (1: 4)	5.9601	1.38	2.00	69.5%
RETL D10(Dx) (Gy)	> 10 (1: 4)	5.9643	1.35	2.00	67.3%
CHIASM Max dose (Gy)	> 37.5	31.0066	0.00	0.00	0%
LOOPTIC Max dose (Gy)	> 37.5	30.7984	0.00	0.00	0%
PROPTIC Max dose (Gy)	> 37.5	30.9983	0.00	0.00	0%
BRAINSTEM Max dose (Gy)	> 37.5	31.9720	0.00	0.00	0%
ICOM Max dose (Gy)	> 37.5	28.1153	0.00	0.00	0%
Total (24 Metrics)		91.55	100.00	91.55	


Results




Results



Discussion / Usage Variation



Variation: Number of arcs
This model was validated with 4 arcs (2 vertex). However, in practice, users have had good results using 3-4 coplanar arcs with collimator rotation 315, 45, 90. PQM report score 91.55 (methods section) and isodose distribution shown below are both generated by this model with 3 full coplanar arcs.



Conclusion

This HCSWB RapidPlan model creates high quality plans, with low variability created efficiently (no modification to auto-created optimization objectives) with specific metrics based on NRG-CC001. This RapidPlan model is available to download (free) on www.Oncopeer.com, with the full PDF description document. Like all RapidPlan models it can also be modified, if required, to meet other planning goals.

Contact

Vanessa Magliari
St Anthony's Medical Center
Saint-Louis, MO
Email: vanessa@magliari.com

References

1. A Randomized Phase III Trial of Mammalian and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients with Brain Metastases <https://www.nrgoncology.org/Clinical-Trials/NRG-CC001>
2. Nelms et al, PRO 214, 296 (2012)
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.